Sonoma Pharmaceuticals, Inc.
SNOA Healthcare Drug Manufacturers Specialty & Generic
Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
Follow SNOA
Sonoma Pharmaceuticals, Inc. (SNOA) Altman Z-score
Sonoma Pharmaceuticals, Inc.'s Altman Z-score for fiscal 2026 is −18.52, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −18.52 | 0.63 |
| FY2025 | −19.15 | (1.33) |
| FY2024 | −17.82 | (2.35) |
| FY2023 | −15.47 | (2.72) |
| FY2022 | −12.75 | 1.87 |
| FY2021 | −14.63 | 1.57 |
| FY2020 | −16.19 | (0.46) |
| FY2019 | −15.73 | (6.08) |
| FY2018 | −9.65 | (6.04) |
| FY2017 | −3.62 | 11.30 |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.52 | — | 0.62 | |
| Retained earnings / total assets | (14.40) | — | −20.16 | |
| EBIT / total assets | (0.18) | — | −0.58 | |
| Market value of equity / total liabilities | 0.33 | — | 0.20 | |
| Sales / total assets | 1.40 | — | 1.40 | |
| Altman Z-score | Distress zone | −18.52 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −44.40 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GELS Gelteq Limited compare | 0.4× |
| BFRI Biofrontera Inc. compare | −5.7× |
| PRFX PainReform Ltd. compare | −7.9× |
| INM InMed Pharmaceuticals Inc. compare | −10.3× |
| SNOA Sonoma Pharmaceuticals, Inc. | −18.5× |
| YCBD cbdMD, Inc. compare | −21.7× |
| RDHL Redhill Biopharma Ltd. compare | −24.4× |
| AKAN Akanda Corp. compare | −26.4× |
| APUS Apimeds Pharmaceuticals US, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets